Screener
Allogene Therapeutics ALLO Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$42.68M+16.2% | -$42.61M+28.7% | -$38.81M+35.3% | -$41.4M+37.5% | -$50.94M+23.2% | ||
| $2.65M-14.8% | $2.87M-7.4% | $3.06M-5.4% | $3.1M-3.4% | $3.11M-14.8% | ||
| $12.44M+43.2% | $8.27M-32.1% | $8.13M-36.8% | $8.65M-35.4% | $8.69M-35.9% | ||
| -$32M+18.0% | -$12.91M+75.6% | -$27.6M+24.8% | -$29.69M+32.7% | -$39.03M+38.6% | ||
| $150K+241% | $9K-90.9% | $0-100% | $243K-43.4% | $44K— | ||
| -$147.56M-437% | -$29.59M-579% | $33.61M-38.8% | $11.94M— | $43.84M-41.3% | ||
| $187.87M+3,604% | $21.12M+51.0% | $7.86M+36.8% | $3.24M+377% | $5.07M-95.3% | ||
| —— | -$21.38M+34.7% | —— | -$14.52M+87.8% | —— | ||
| -$32.15M+17.7% | -$12.92M+75.6% | -$27.6M+25.3% | -$29.93M+32.8% | -$39.07M+38.6% |
FAQ
- How much cash does Allogene Therapeutics generate?
- Allogene Therapeutics (ALLO) generated -$102.2M in operating cash flow over the trailing twelve months.
- What is Allogene Therapeutics's free cash flow?
- After $402.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$102.6M over the trailing twelve months, up 40.9% year over year.
- Where does Allogene Therapeutics's cash flow data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
